Advancing Novel Covalent Therapies to the Clinic 

Developing Safe & Effective Covalent Therapeutics With Novel Screening Technology, Tailored Assays & Clinical Translation Strategies to Target the Undruggable

Covalent drug discovery has entered a defining new phase where scientific validation is no longer the primary barrier; successful clinical translation now takes center stage.

Once limited by concerns around off-target toxicity, covalent approaches are now unlocking undruggable targets and expanding beyond oncology into new therapeutic areas. As next-generation warheads, chemoproteomics, and AI-driven design accelerate innovation, the key challenge is clear: how to translate covalent candidates into safe, effective clinical therapies.

The 4th Covalent Drug Discovery & Development Summit is the only industry forum dedicated to advancing covalent therapeutics end-to-end, from discovery through to IND and early clinical development.

Uniting experts from Bristol Myers Squibb, Novartis, Pfizer, Biogen, Nexo Therapeutics, and Frontier Medicines, this summit goes beyond high-level discussion to deliver data-driven case studies, translational strategies, and real clinical insights.

Join 80+ covalent leaders to:

De-risk your pipeline with early clinical and translational learnings
Overcome selectivity, safety, and PK/PD challenges
Gain candid insights not found in publications

As more covalent drugs enter the clinic, now is the time to turn promise into proof.

Download the Agenda

There is so much need in medicine that no single company can address, but as a community we can create more value for all.  Seeing different scientific approaches, meeting with peers, receiving critiques makes us all more successful.

Dean Stamos, Co-Founder & Chief Scientific Officer, Expedition Medicines

The meeting brings together like-minded covalent enthusiasts and experts in the same room for thoughtful discussions.

Jaimeen Devraj, Associate Research Fellow, Pfizer

I see strong value in a focused platform that provides comprehensive coverage of today's covalent drug discovery and fosters cross-disciplinary exchange.

Weixue Wang, Senior Director, Antares Therapeutics